HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.

Abstract
The objective of this study was to investigate the cytotoxic activity of irofulven (HMAF, MGI 114), a unique chemotherapeutic agent currently under clinical investigation, in various preclinical models of ovarian cancer. Antiproliferative effects of irofulven in ovarian cancer cell lines and ovarian tumor specimens were characterized in vitro using sulforhodamine B and human tumor colony-forming assays, respectively. Irofulven demonstrated marked activity against a panel of ovarian tumor cell lines, including IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SK-OV-3, all of which exhibit various drug resistance mechanisms. In human tumor cloning assays, irofulven inhibited colony formation in surgically derived ovarian tumors at concentrations as low as 0.001 micro g /ml and indicated superior activity in comparison with paclitaxel when tested against the same tumor specimens. The antitumor activity of irofulven compared to that of paclitaxel was also examined using the SK-OV-3 xenograft model. In mice bearing subcutaneously implanted SK-OV-3 tumors, treatment with paclitaxel failed to inhibit tumor growth; whereas mice treated with maximum tolerated doses of irofulven had a 25% partial shrinkage rate, and the remaining animals had a mean tumor growth inhibition of 82%. The potent activity of irofulven against ovarian tumors in vitro and in vivo supports the evaluation of its clinical activity in ovarian cancer.
AuthorsE S van Laar, E Izbicka, S Weitman, L Medina-Gundrum, J R Macdonald, S J Waters
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) 2004 Sep-Oct Vol. 14 Issue 5 Pg. 824-31 ISSN: 1048-891X [Print] England
PMID15361190 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Sesquiterpenes
  • irofulven
Topics
  • Animals
  • Antineoplastic Agents, Alkylating (pharmacology)
  • Carcinoma (drug therapy, pathology)
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Mice
  • Mice, Nude
  • Neoplasms, Experimental
  • Ovarian Neoplasms (drug therapy, pathology)
  • Sesquiterpenes (pharmacology)
  • Transplantation, Heterologous
  • Tumor Cells, Cultured
  • Tumor Stem Cell Assay

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: